Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Faeth Therapeutics, Inc.SNSE · Entity 5029 | CHIEF FINANCIAL OFFICER | February 15, 2024 | February 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Faeth Therapeutics, Inc.
Report date February 15, 2024 · Filed February 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,462 |
Reported balance
After 2024-02-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-02-15 · Tax withholding · Disposed 3,627 · Balance 67,462 F1: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. F2: Includes 3,000 shares purchased by the Reporting Person on May 16, 2023 pursuant to the Issuer's 2021 Employee Stock Purchase Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2034-02-14 | Direct | 125,000 |
Reported balance
After 2024-02-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-15 · Grant · Acquired 125,000 · Balance 125,000 F3: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2025, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2034-02-14 | Direct | 94,128 |
Reported balance
After 2024-02-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-15 · Grant · Acquired 94,128 · Balance 94,128 F4: Represents one-third of the Reporting Person's 2023 annual bonus, which the Compensation Committee of the Issuer determined to pay in the form of a stock option in lieu of cash. 100% of the shares are fully vested as of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.
F2: Includes 3,000 shares purchased by the Reporting Person on May 16, 2023 pursuant to the Issuer's 2021 Employee Stock Purchase Plan.
F3: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2025, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
F4: Represents one-third of the Reporting Person's 2023 annual bonus, which the Compensation Committee of the Issuer determined to pay in the form of a stock option in lieu of cash. 100% of the shares are fully vested as of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2024 Filed Feb 16, 2024 23:25 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 94,128 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001415889-24-004234 · form4-02162024_110205.xml · derivative · entry 3 Colgan Erin · CIK 0001843563 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,128 Underlying: Common Stock · 94,128 shares Expires 2034-02-14 F4 · derivative.exercise_date: Represents one-third of the Reporting Person's 2023 annual bonus, which the Compensation Committee of the Issuer determined to pay in the form of a stock option in lieu of cash. 100% of the shares are fully vested as of the date of grant. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 23:25 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001415889-24-004234 · form4-02162024_110205.xml · derivative · entry 2 Colgan Erin · CIK 0001843563 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-02-14 F3 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2025, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 23:25 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | Tax withholdingCommon Stock | 3,627 | $0.79 | $2,865.33 |
DisclosureSEC source: 0001415889-24-004234 · form4-02162024_110205.xml · nonDerivative · entry 1 Colgan Erin · CIK 0001843563 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,462 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 3,000 shares purchased by the Reporting Person on May 16, 2023 pursuant to the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:01 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-23-010735 · doc4.xml · derivative · entry 3 Colgan Erin · CIK 0001843563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-02-14 F3 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:01 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 21,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010735 · doc4.xml · nonDerivative · entry 2 Colgan Erin · CIK 0001843563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,032 F2 · shares: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:01 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 30,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010735 · doc4.xml · nonDerivative · entry 1 Colgan Erin · CIK 0001843563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,732 F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested. Read SEC document |
| February 15, 2023 Filed Mar 29, 2023 21:17 UTC Amendment | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-23-021542 · doc4a.xml · derivative · entry 3 Colgan Erin · CIK 0001843563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-02-14 F5 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| February 15, 2023 Filed Mar 29, 2023 21:17 UTC Amendment | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 21,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021542 · doc4a.xml · nonDerivative · entry 2 Colgan Erin · CIK 0001843563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,032 F4 · shares: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date. F1 · balance_after: This amendment is being filed solely to correct the number of shares beneficially owned. Due to administrative error the original filing did not include shares purchased under the Issuer's Employee Stock Purchase Plan ("ESPP"). F3 · balance_after: Share balance includes stock purchased under the ESPP not previously reported. Read SEC document |
| February 15, 2023 Filed Mar 29, 2023 21:17 UTC Amendment | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 30,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021542 · doc4a.xml · nonDerivative · entry 1 Colgan Erin · CIK 0001843563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,732 F1 · security: This amendment is being filed solely to correct the number of shares beneficially owned. Due to administrative error the original filing did not include shares purchased under the Issuer's Employee Stock Purchase Plan ("ESPP"). F2 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested. F1 · balance_after: This amendment is being filed solely to correct the number of shares beneficially owned. Due to administrative error the original filing did not include shares purchased under the Issuer's Employee Stock Purchase Plan ("ESPP"). F3 · balance_after: Share balance includes stock purchased under the ESPP not previously reported. Read SEC document |
| February 15, 2023 Filed Sep 11, 2023 21:31 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | Tax withholdingCommon Stock | 10,943 | $1.50 | $16,414.50 |
DisclosureSEC source: 0001209191-23-048965 · doc4.xml · nonDerivative · entry 1 Colgan Erin · CIK 0001843563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,089 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:21 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001209191-22-010978 · doc4.xml · derivative · entry 2 Colgan Erin · CIK 0001843563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2032-02-14 F3 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2023; and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:21 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010978 · doc4.xml · nonDerivative · entry 1 Colgan Erin · CIK 0001843563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,686 F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2023, February 15, 2024, February 15, 2025 and February 15, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. F2 · balance_after: Includes 686 shares acquired by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:38 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 52,083 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008085 · doc4.xml · derivative · entry 1 Colgan Erin · CIK 0001843563 · SVP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,083 Underlying: Common Stock · 52,083 shares Expires 2031-02-02 F1 · derivative.exercise_date: One-fourth (1/4th) of the options granted hereby shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, February 3, 2021, thereafter one forty-eighth (1/48th) of the options granted shall vest and become exercisable each month following the Vesting Commencement Date, over four years such that the options shall be 100% vested on the fourth anniversary of the Vesting Commencement Date, subject to the grantee's Continuous Service (as defined in the 2021 Equity Incentive Plan) through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.